Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Prosopis farcta* fruit extract is a botanical preparation derived from the Syrian mesquite, a plant native to the Middle East. It has been primarily investigated for its gastroprotective and anti-inflammatory properties in the treatment of gastric ulcers and ulcerative colitis. The extract's mechanism of action involves the suppression of pro-inflammatory cytokines, specifically tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta), which are key mediators of mucosal damage. Additionally, it exerts cytoprotective effects by reducing gastric acid secretion and stimulating the production of protective mucus, thereby maintaining the structural integrity of the gastrointestinal lining. Preclinical studies in rat models have demonstrated its efficacy in preventing morphological changes such as inflammation and necrosis induced by agents like indomethacin or acetic acid.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prosopis farcta fruit extract.